- Companies
- Mainstay Medical
Mainstay Medical Funding, Investors & Competitors
Mainstay Medical has raised $270M across 3 funding rounds, most recently a $125M undisclosed-stage round in February 2024.
Last Mainstay Medical funding round
$125M
Undisclosed stage · Feb 2024
Cumulative funding Mainstay Medical raised
$270M
across 3 funding rounds
Key investors in Mainstay Medical
Sofinnova Partners
Ally Bridge Group
Fountain Healthcare Partners
Perceptive Advisors
Viking Global Investors
Gilde Healthcare
Ireland Strategic Investment Fund
KCK
About Mainstay Medical
Mainstay Medical is a Dublin-headquartered medical device company developing the ReActiv8 implantable neurostimulation system for chronic low back pain. The FDA-approved device delivers electrical stimulation to the muscles of the lower back during specific restorative exercises, targeting patients unresponsive to conventional therapies. Mainstay conducts clinical trials across Europe and the United States, with commercial operations in Australia, Germany, and the UK. Listed on Euronext and NASDAQ, the company partners with pain management clinics and spine specialists to address the needs of over 10 million sufferers worldwide. Established in 2008, Mainstay employs around 100 staff globally.
Founded
2008
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales, Subscription
Mainstay Medical Funding History
Mainstay Medical has raised a total of $270M across 3 funding rounds.
Mainstay Medical's first fundraising round was a $37M undisclosed-stage round in February 2018. The most recent completed round was a $125M undisclosed-stage round in February 2024.
Mainstay Medical funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Feb 2024 | Undisclosed stage | Gilde Healthcare (lead); Viking Global Investors (lead); Sofinnova Partners; Fountain Healthcare Partners; Ally Bridge Group; Perceptive Advisors | $125M | Mainstay Medical, an Irish medical device company, develops ReActiv8, a restorative neurostimulation implant for treating mechanical chronic low back pain associated with multifidus muscle dysfunction. The device has received CE mark in Europe (2016), approval in Australia (2019), FDA approval in the US (2020), and an expanded FDA label for 1.5T full-body MRI compatibility earlier in 2024. ReActiv8 began US commercialization in 2021 and aims to demonstrate superiority over therapies designed for other indications through clinical and health economic data. On February 26, 2024, Mainstay Medical closed a $125 million equity financing round co-led by new investors Gilde Healthcare and Viking Global Investors, with participation from existing investors Ally Bridge Group, Sofinnova Partners (Crossover Fund), Fountain Healthcare Partners, and Perceptive Advisors. The funds will support commercial expansion of ReActiv8 in the US, Europe, and Australia, build on insurance coverage including the first national US policy with Anthem BCBS, generate additional post-market clinical studies and research, and cover general operations and IP development. Gilde Healthcare's Geoff Pardo joined the board. The financing followed two extraordinary general meetings on February 23, 2024, where all resolutions passed. CEO Jason Hannon highlighted the round's scale to accelerate growth and capitalize the company for objectives like rapid commercial progress and data generation to support ReActiv8's unique mechanism. |
| Feb 2021 | Undisclosed stage | Ally Bridge Group (lead); Sofinnova Partners (lead); KCK; Fountain Healthcare Partners | $108M | Mainstay Medical is a medical device company headquartered in Dublin, Ireland, focused on commercializing ReActiv8, an implantable restorative neurostimulation system for treating mechanical chronic low back pain (CLBP). The company has subsidiaries in the US, Australia, Germany, Netherlands, and elsewhere to support commercialization. On February 16, 2021, Mainstay closed a US$108 million equity financing co-led by new investors Ally Bridge Group and Sofinnova Partners (Crossover Fund), with participation from a large global medical device company and existing investors including Sofinnova Partners (Capital Fund), KCK Group, and Fountain Healthcare Partners. The proceeds were intended to fund the US commercial launch of ReActiv8, expansion in Europe and Australia, post-market clinical studies, research, and general operations. This financing underscored investor confidence in ReActiv8's commercial potential as a unique restorative therapy for CLBP patients with limited options. Charles Chon from Ally Bridge Group and Cédric Moreau from Sofinnova Partners joined the board post-investment. Jason Hannon, CEO, highlighted the syndicate's quality and the company's strengthened position for 2021 objectives, including US market entry and accelerated commercialization. The round involved issuing new preferred shares, with Ally Bridge later holding about 27.6% of issued share capital by end-2021. For the fiscal year ending December 31, 2021, Mainstay reported revenue of $5.3 million, up from $1.5 million in 2020, reflecting commercial growth. Revenue doubled to $10.1 million in 2022. The company remained in a loss-making phase, with a $35.7 million loss in 2021 increasing to $49.1 million in 2022 amid R&D and expansion investments. Cash position supported operations post-financing, with total assets at $87.9 million at end-2021, declining to $56.0 million by end-2022. |
| Feb 2018 | Undisclosed stage | Ireland Strategic Investment Fund | $37M | Mainstay Medical announced a EUR 30 million equity financing in February 2018 in which the Ireland Strategic Investment Fund invested approximately EUR 10 million, subscribing for 714,285 new shares, or about 33.2 per cent of the new shares issued. The remainder of the round came from Mainstay's existing long-term shareholders Sofinnova Partners, Fountain Healthcare Partners and KCK, together with a number of individual investors. Mainstay said the proceeds would fund completion of the ReActiv8-B clinical study, the filing of a pre-market approval application with the US Food and Drug Administration, and the build-out of a commercial presence ahead of a wider launch. Mainstay Medical was founded in 2008 and is headquartered in Dublin, with operations in Ireland, the United States and Australia, and its shares were listed on Euronext Paris and Euronext Dublin at the time of the transaction. Its lead product, ReActiv8, is an implantable neurostimulator designed to restore control of the muscles that stabilise the lumbar spine in patients with chronic mechanical low back pain. |
Who has invested in Mainstay Medical?
8 investors have backed Mainstay Medical across its funding rounds, including Sofinnova Partners, Ally Bridge Group, Fountain Healthcare Partners, Perceptive Advisors, Viking Global Investors and Gilde Healthcare.
Lead investors include Gilde Healthcare, Viking Global Investors, Ally Bridge Group and Sofinnova Partners.
Mainstay Medical Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Feb 2021 | ||
| 2 | Participant | Feb 2021 | ||
| 2 | Lead | Feb 2021 | ||
| 1 | Participant | Feb 2021 | ||
| 1 | Lead | Feb 2024 | ||
| 1 | Participant | Feb 2018 | ||
This data is available for Pro users. Sign up to see all 8 Mainstay Medical investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialMainstay Medical Competitors
Mainstay Medical competitors include listed companies like IDEXX Laboratories, GE HealthCare, United Imaging and Glaukos, and private ones like Dental Monitoring and AcuityMD.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $4.3B | $1.5B | $40B | 8.9x | ||
| Publicly listed | $21B | $3.7B | $29B | 1.8x | ||
| Publicly listed | $2.1B | $367M | $12B | 4.8x | ||
| Publicly listed | $507M | ($157M) | $9.5B | 14.6x | ||
| Private | $91M | - | $1B | - | ||
| Private | - | - | $955M | - |
Mainstay Medical Public Comps
Mainstay Medical is still privately-owned, but its public comps include Samsung, Johnson & Johnson, Roche, Thermo Fisher Scientific, Siemens, Abbott, Danaher, Intuitive Surgical, Medtronic and Stryker.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $243B | $67B | 4.4x | 2.4x | 15.8x | 4.4x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $45B | $11B | 6.3x | 6.0x | 26.8x | 23.6x | |||
| $91B | $15B | 3.0x | 2.9x | 18.1x | 15.7x | |||
| $44B | $12B | 4.6x | 4.2x | 17.4x | 15.8x | |||
| $25B | $6.9B | 7.0x | 6.6x | 24.8x | 21.1x | |||
| $10B | $3.6B | 13.0x | 11.6x | 36.6x | 25.7x | |||
This data is available for Pro users. Sign up to see all Mainstay Medical competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Mainstay Medical
| When was Mainstay Medical founded? | Mainstay Medical was founded in 2008. |
| Where is Mainstay Medical headquartered? | Mainstay Medical is headquartered in Dublin, Ireland. |
| Is Mainstay Medical publicly listed? | No, Mainstay Medical is a private, VC-backed company. |
| How much funding has Mainstay Medical raised? | Mainstay Medical has raised $270M across 3 funding rounds. |
| What was Mainstay Medical's last funding round? | Mainstay Medical's last funding round was a $125M undisclosed-stage round in February 2024, led by Gilde Healthcare and Viking Global Investors. |
| Who are Mainstay Medical's investors? | Mainstay Medical's investors include Sofinnova Partners, Fountain Healthcare Partners, Ally Bridge Group, KCK, Gilde Healthcare, Ireland Strategic Investment Fund, Viking Global Investors and Perceptive Advisors. |
| Which companies are comparable to Mainstay Medical? | Companies comparable to Mainstay Medical include IDEXX Laboratories, GE HealthCare, United Imaging, Glaukos, Dental Monitoring and AcuityMD. |
See companies similar to Mainstay Medical
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




